(Q53540501)

English

Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. (English)

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

quality of life

1 reference

based on heuristic

inferred from title

Cynthia J Girman

2

object named as

Girman CJ

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

author name string

Bruskewitz R

1

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

Fowler J

3

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

Rigby OF

4

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

Sullivan M

5

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

Bracken RB

6

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

Fusilier HA

7

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

Kozlowski D

8

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

Kantor SD

9

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

Johnson EL

10

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

Wang DZ

11

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

Waldstreicher J

12

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

language of work or name

0 references

publication date

1 October 1999

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

54

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

4

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

670-678

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of a new quality of life questionnaire for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of a symptoms questionnaire for benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevalence of prostatism: a population-based survey of urinary symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Similar levels of urological symptoms have similar impact on Scottish and American men--although Scots report less symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A brief male sexual function inventory for urology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined analysis of two multicenter studies of finasteride 5 mg in the treatment of symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Finasteride to prevent morbidity from benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Association of health-related quality of life and benign prostatic enlargement.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The International Continence Society “Benign Prostatic Hyperplasia” Study: The Bothersomeness of Urinary Symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A new patient weighted symptom score system (DAN-PSS-1). Clinical assessment of indications and outcomes of transurethral prostatectomy for uncomplicated benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term quality of life in patients with benign prostatic hypertrophy: preliminary results of a cohort survey of 7,093 patients treated with an alpha-1-adrenergic blocker, alfuzosin. QOL BPH Study Group in General Practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of prostatism: Factors associated with discordance between frequency and bother of urinary symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Health-related quality of life associated with lower urinary tract symptoms in four countries.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of prostatism: risk factors for acute urinary retention

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptoms and signs of prostatism as risk factors for prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900209-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0090-4295(99)00209-5

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

1 reference

Europe PubMed Central

15 May 2018

http://europepmc.org/abstract/MED/10510926

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53540501&oldid=1838104192"